Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05180591 · ClinicalTrials.gov registry record · Phase 2
Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes
A Phase 2 study of Diabetes Mellitus, Type 1 and Autoimmune Diabetes, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT05180591 is a Phase 2 study of Diabetes Mellitus, Type 1 and Autoimmune Diabetes that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 150 participants, below the 1,265-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05180591, a Phase 2 study of Diabetes Mellitus, Type 1 and Autoimmune Diabetes, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate if repeat bacillus Calmette-Guérin (BCG) vaccinations can confer a beneficial immune and metabolic effect on pediatric Type 1 diabetes.
Conditions Studied
Interventions
- BIOLOGICAL Bacillus Calmette-Guérin
- BIOLOGICAL Saline Injection
Study Locations (1)
Massachusetts
- Immunobiology Labs CNY 149 - Charlestown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2022-03-22 |
| Est. Completion | 2027-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05180591
The ClinicalTrials.gov registry entry for NCT05180591 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,265-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (88% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 2 interventions - of which Bacillus Calmette-Guérin is the first listed.
NCT05180591 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05180591 about?
NCT05180591 is a clinical study titled "Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes". The purpose of this study is to investigate if repeat bacillus Calmette-Guérin (BCG) vaccinations can confer a beneficial immune and metabolic effect on pediatric Type 1 diabetes.
What is the current status of trial NCT05180591?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2022-03-22. Estimated completion is 2027-03.
What conditions does trial NCT05180591 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 1, Autoimmune Diabetes, Diabetes type1.
What interventions are being tested in trial NCT05180591?
The interventions under investigation include: Bacillus Calmette-Guérin (BIOLOGICAL), Saline Injection (BIOLOGICAL).
Who is sponsoring clinical trial NCT05180591?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05180591 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Islet Transplantation in Type 1 Diabetic Kidney Allograft
RECRUITING · Phase 2
-
Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec
ACTIVE NOT RECRUITING · Phase 2
-
Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients
ACTIVE NOT RECRUITING · Phase 2
-
Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
ACTIVE NOT RECRUITING · Phase 2
-
Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control
COMPLETED · Phase 2
-
To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.